Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in Rest of World: $272M in Q3 2026, up 67.9% from a year earlier.
Latest, Q3 2026
272
Period ended Sep 30, 2026
Change on a year earlier
+67.9%
162 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
11
Documents cited below
Where the Q3 2026 figure comes from
“|| Leqvio | Cardiovascular, renal and metabolic | Atherosclerotic cardiovascular disease (ASCVD) | 234 | 60 | 272 | 68 | 65 | 506 | 64 | 63”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in Rest of World ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 272 | +67.9% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 266 | +66.3% | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 286 | +120.0% | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 171 | +59.8% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 162 | +67.0% | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | 160 | +81.8% | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 130 | +68.8% | Novartis Form 6-K (0001370368-25-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | 107 | – | Novartis Form 6-K (0001370368-25-000007) ↗ |
| Q3 2024 | Sep 30, 2024 | 97 | – | Novartis Form 6-K (0001370368-24-000022) ↗ |
| Q2 2024 | Jun 30, 2024 | 88 | – | Novartis Form 6-K (0001370368-24-000019) ↗ |
| Q1 2024 | Mar 31, 2024 | 77 | – | Novartis Form 6-K (0001370368-24-000017) ↗ |
Breakdown
What makes up net Sales in Rest of World
Cite this data
StockData. (2026). Novartis Net Sales in Rest of World ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-leqvio-row-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.